GGrantIndex
Sort

48,018 grants matching immunotherapy

EASTERN COOPERATIVE ONCOLOGY GROUP

$411,364
University Of Pennsylvania · U10 · FY2001 · CA

Target-specific inhibition and activation of protein tyrosine phosphatases

$411,330
Anthony C Bishop · Amherst College · R15 · FY2021 · GM

Development of mAb immunotherapy for genetically modified plague

$411,313
James B Bliska · Columbia University Health Sciences · U54 · FY2011 · AI

Regulation of host immunity to impact virus persistence

$411,274
Bumsuk Hahm · University Of Missouri-Columbia · R01 · FY2022 · AI

NK cell responses to JC polyomavirus

$411,250
Chen Sabrina Tan · Beth Israel Deaconess Medical Center · R01 · FY2021 · NS

NK cell responses to JC polyomavirus

$411,250
Chen Sabrina Tan · Beth Israel Deaconess Medical Center · R01 · FY2020 · NS

NK cell responses to JC polyomavirus

$411,250
Chen Sabrina Tan · Beth Israel Deaconess Medical Center · R01 · FY2022 · NS

Lineage Specific Effects of IL10 In Autoimmunity

$411,250
Terrence L Geiger · St. Jude Children'S Research Hospital · R56 · FY2013 · AI

Cellular Mechanisms of PTLD in Transplant Recipients

$411,227
Olivia M Martinez · Stanford University · R01 · FY2010 · AI

Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma development

$411,223
Humam Kadara · University Of Tx Md Anderson Can Ctr · U01 · FY2024 · CA

MATCHMAKERS: Solving T-cell receptor recognition and design via integrated high-throughput screening and structural, functional and computational approaches

$411,201
Stephen J Elledge · Brigham And Women'S Hospital · OT2 · FY2025 · CA

Cancer and Leukemia Group B

$411,171
Dana-Farber Cancer Institute · U10 · FY2004 · CA

EGFRvIII-targeted Bispecific T cell Engagers for brain tumors

$411,170
John H Sampson · Duke University · R01 · FY2013 · NS

Biomimetic Zwitterionic Functional Materials for Immunomodulation

$411,138
Jiang Shaoyi · Cornell University · · FY2020 · MPS

Contribution of the cutaneous APC network to melanoma progression and therapy.

$411,038
Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2014 · CA

Collaborative Innate-Adaptive Immune Regulation of Tumor Progression

$410,978
Matthew F Krummel · University Of California, San Francisco · U01 · FY2012 · CA

Developing a Translation Pipeline for VHL Mutant Malignancies

$410,974
David McDermott · Beth Israel Deaconess Medical Center · U01 · FY2020 · CA

TLR5 signaling as a conserved mechanism of impaired anti-tumor immunity

$410,973
Melanie R Rutkowski · University Of Virginia · R01 · FY2025 · CA

Understanding the Mechanism of Mucosal Immunotherapy

$410,941
Arvil Wesley Burks · Duke University · R01 · FY2010 · AI

Targetable Immune Evasion Pathways in Hodgkin Lymphoma

$410,899
Margaret A Shipp · Dana-Farber Cancer Inst · R01 · FY2016 · CA

SOUTHWEST ONCOLOGY GROUP - OPERATIONS OFFICE

$410,890
Cancer Therapy And Research Center · U10 · FY2005 · CA

Targeted activation of autoimmune checkpoints in B cell malignancies

$410,875
Markus Mãœschen · Beckman Research Institute/City Of Hope · R01 · FY2017 · CA

Targeted activation of autoimmune checkpoints in B cell malignancies

$410,875
Markus Mãœschen · Beckman Research Institute/City Of Hope · R01 · FY2020 · CA

Immunoengineered nanotechnology for targeted expansion of regulatory T cells

$410,855
Jamie Berta Spangler · Johns Hopkins University · R01 · FY2023 · EB

Binding and Presentation of Lipid Antigens by CD1

$410,850
Steven A Porcelli · Albert Einstein College Of Medicine · R01 · FY2010 · AI